Jürg Eckhardt

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA.

ProSanos Corp. develops and provides healthcare solutions for the pharmaceutical and biotechnology industries. The company was founded by Jonathan A. Morris and Michael N. Liebman in 2000 and is headquartered in Harrisburg, PA.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.

Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The company is based in St. Peter Port, UK.

Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA.

BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA.

BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA.

Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ.

POSCO BioVentures Inc (POSCO BioVentures) is a venture capital subsidiary of POSCO America Corp founded in 2002 by Leo Kim. The firm is headquartered in Carlsbad, California.

eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA.

Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA.

AgResearch Ltd. engages in research and development activities in the pastoral sector. It offers NaturOTM analgesia system, CARLA Saliva Test, WormFEC and MicroManual products. Its services include bioinformatics, development engineering, farms and deoxyribonucleic acid testing laboratory. The company was founded in 1992 and is headquartered in Hamilton, New Zealand.

9905553 Canada, Inc. operates as a digital market place that allows buyers and sellers to list, negotiate, and finalize grain deals. The company was founded by Brennan Turner and Alain Goubau and is headquartered in Ontario, Canada.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.

Cameron Health, Inc. develops medical devices for patients and medical professionals. It has developed a totally subcutaneous implantable defibrillator (S-ICD) system that remedies many of the issues associated with traditional implantable cardioverter defibrillators. The company was founded on August 21, 2000 and is headquartered in San Clemente, CA.

swiss smile Holding AG operates as a holding company with interests in operates a chain of dental clinics. It offers treatments in the areas of aesthetic dentistry, bleaching, implantology, orthodontic, oral surgery, endodontic, pediatric dentistry, periodontology, professional teeth cleaning, bad breath, prosthetic, tooth-colored filling, teeth grinding, general anesthetic, and emergency aspects. The firm also provides whitening toothpastes, herbal toothpastes, whitening toothbrushes, soft toothbrushes, waxed dental tapes, and interdental brushes. The company was founded by Haleh Abivardi Brönner and Golnar Abivardi Signer in 2006 and is headquartered in Zurich, Switzerland.

Anteis SA modifies and functionalizes injectable hyaluronic acid for medical applications. The firm serves in Asthetic dermatology. The company was founded by Gilles Bos Gilles in March 2003 and is headquartered in Plan-les-Ouates, Switzerland.

Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland.

Pairwise Plants LLC operates as a agriculture company. The company was founded by Feng Zhang, David Liu and J. Keith Joung and is headquartered in Durham, NC.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Plant Response, Inc. is engaged in providing agricultural biological services. It offers cybelion, power coat, biohp, neptunion, biopath and PRB9 products. The company is headquartered in Durham, NC.

Casebia Therapeutics LLP provides physical, chemical, and analytical testing services. The British company was founded in 2016, and Jim Burns has been the CEO of the company since 2019.

Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada.

Joyn Bio LLC is a joint venture between Leaps by Bayer and Ginkgo Bioworks that engineers microbes to improve naturally occurring processes in agriculture. The company is based in Boston, MA, and has two sites for leading scientists with diverse backgrounds. The company's focus is on developing probiotics for plants to provide growers with next-generation solutions to their biggest challenges. The company's first area of focus is on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture's reliance on nitrogen fertilizer and its environmental impact.

Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky.